CL2021000175A1 - Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos - Google Patents

Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos

Info

Publication number
CL2021000175A1
CL2021000175A1 CL2021000175A CL2021000175A CL2021000175A1 CL 2021000175 A1 CL2021000175 A1 CL 2021000175A1 CL 2021000175 A CL2021000175 A CL 2021000175A CL 2021000175 A CL2021000175 A CL 2021000175A CL 2021000175 A1 CL2021000175 A1 CL 2021000175A1
Authority
CL
Chile
Prior art keywords
preventing
same
pharmaceutical compositions
cancers including
treating cancers
Prior art date
Application number
CL2021000175A
Other languages
English (en)
Inventor
Jae Yul Choi
In Hwan Bae
Ji Sook Kim
Seok Jong Kang
Young Gil Ahn
Kwee Hyun Suh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2021000175A1 publication Critical patent/CL2021000175A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

Se proporciona un compuesto de pirimidina representado por la Fórmula 1, un método para preparar el compuesto, y un uso farmacéutico del compuesto para la prevención o el tratamiento del cáncer.
CL2021000175A 2018-07-25 2021-01-22 Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos CL2021000175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180086768A KR101954370B1 (ko) 2018-07-25 2018-07-25 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
CL2021000175A1 true CL2021000175A1 (es) 2021-07-02

Family

ID=65760263

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000175A CL2021000175A1 (es) 2018-07-25 2021-01-22 Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos

Country Status (16)

Country Link
US (2) US11292786B2 (es)
EP (1) EP3810601A4 (es)
JP (1) JP6806931B2 (es)
KR (1) KR101954370B1 (es)
CN (2) CN116693506A (es)
AR (1) AR119657A1 (es)
BR (1) BR112021001122A2 (es)
CA (1) CA3106961A1 (es)
CL (1) CL2021000175A1 (es)
DO (1) DOP2021000017A (es)
MX (1) MX2021000941A (es)
PE (1) PE20210373A1 (es)
PH (1) PH12021550124A1 (es)
SG (1) SG11202100076RA (es)
WO (1) WO2020022600A1 (es)
ZA (1) ZA202100485B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212153A1 (es) * 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
CA3145391A1 (en) * 2019-06-27 2020-12-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
WO2021066443A1 (ko) * 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
JP2023548190A (ja) * 2020-11-05 2023-11-15 ハンミ ファーマシューティカル カンパニー リミテッド 骨髄性白血病の治療のためのｆｌｔ３阻害剤を含む医薬組成物
EP4297873A1 (en) * 2021-02-26 2024-01-03 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
KR102585193B1 (ko) * 2021-04-08 2023-10-06 주식회사 스탠다임 신규한 lrrk2 억제제
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20230056331A (ko) * 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180010A (ja) * 1982-04-15 1983-10-21 Daihen Corp ３相用自動電圧調整装置のタツプ不揃い検出装置
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN102471339A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
US8957065B2 (en) * 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
CA2944669A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6936815B2 (ja) 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体
DK3514153T3 (da) * 2017-01-26 2021-09-27 Hanmi Pharm Ind Co Ltd Pyrimidinforbindelse og farmaceutisk anvendelse deraf

Also Published As

Publication number Publication date
BR112021001122A2 (pt) 2021-04-13
JP2020527128A (ja) 2020-09-03
CA3106961A1 (en) 2020-01-30
PH12021550124A1 (en) 2021-09-27
DOP2021000017A (es) 2021-04-15
US20200255410A1 (en) 2020-08-13
ZA202100485B (en) 2023-11-29
SG11202100076RA (en) 2021-02-25
MX2021000941A (es) 2021-03-09
KR101954370B1 (ko) 2019-03-05
CN116693506A (zh) 2023-09-05
WO2020022600A1 (en) 2020-01-30
PE20210373A1 (es) 2021-02-26
EP3810601A1 (en) 2021-04-28
TW202014417A (zh) 2020-04-16
JP6806931B2 (ja) 2021-01-06
CN112469715A (zh) 2021-03-09
AR119657A1 (es) 2022-01-05
EP3810601A4 (en) 2022-04-20
US20230002358A1 (en) 2023-01-05
US11292786B2 (en) 2022-04-05

Similar Documents

Publication Publication Date Title
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
AR122788A2 (es) Inhibidores de kras g12c y métodos para su uso
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
AR120700A1 (es) Inhibidores de kras g12c
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CY1121884T1 (el) Αντι-ογκικες ενωσεις
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
ZA202006071B (en) Antiproliferation compounds and uses thereof
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores